

Table S1. The top 100 target kinases identified in CAL51 TNBC cell line using 3D RNAi kinome-wide library screening.

CAL51													
Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol
1	<i>RAC1</i>	35	<i>LYN</i>	69	<i>GUK1</i>	103	<i>PIK3R4</i>	137	<i>PRKCL2</i>	171	<i>MERTK</i>	205	<i>ACVRL1</i>
2	<i>MAP4K4</i>	36	<i>IKBKE</i>	70	<i>PIK4CA</i>	104	<i>PCTK3</i>	138	<i>NME4</i>	172	<i>MAPK14</i>	206	<i>C5R1</i>
3	<i>RASGRF2</i>	37	<i>EPHB1</i>	71	<i>MAPK6</i>	105	<i>AVPR1B</i>	139	<i>NEK4</i>	173	<i>RPS6KA4</i>	207	<i>MAP2K4</i>
4	<i>FUK</i>	38	<i>IL2</i>	72	<i>SNF1LK</i>	106	<i>CCL3</i>	140	<i>ITPK1</i>	174	<i>EEF2K</i>	208	<i>PTPRT</i>
5	<i>GK2</i>	39	<i>PIM1</i>	73	<i>DUSP2</i>	107	<i>GNAI1</i>	141	<i>HIPK3</i>	175	<i>BAI3</i>	209	<i>MAPKAPK3</i>
6	<i>ILK</i>	40	<i>PRKWNK1</i>	74	<i>RAGE</i>	108	<i>STK33</i>	142	<i>FGFR1</i>	176	<i>EDG5</i>	210	<i>GNAI3</i>
7	<i>CARKL</i>	41	<i>PINK1</i>	75	<i>EPHA2</i>	109	<i>MAP4K2</i>	143	<i>PIP5K1A</i>	177	<i>TRIM</i>	211	<i>SNARK</i>
8	<i>PRKCN</i>	42	<i>PIK3R1</i>	76	<i>GNB4</i>	110	<i>ADRBK1</i>	144	<i>HK2</i>	178	<i>NME7</i>	212	<i>TPK1</i>
9	<i>HIPK2</i>	43	<i>LIM</i>	77	<i>CXCL2</i>	111	<i>HK3</i>	145	<i>PLK3</i>	179	<i>MAP3K2</i>	213	<i>GHRHR</i>
10	<i>EPHB6</i>	44	<i>EPHB3</i>	78	<i>MGC5601</i>	112	<i>PIK3CB</i>	146	<i>C14ORF20</i>	180	<i>PHKG1</i>	214	<i>CDK5RAP3</i>
11	<i>CDC2L1</i>	45	<i>HUNK</i>	79	<i>PXK</i>	113	<i>LMTK3</i>	147	<i>MOS</i>	181	<i>PPP2CA</i>	215	<i>MELK</i>
12	<i>PKN3</i>	46	<i>EPHA5</i>	80	<i>STK17A</i>	114	<i>MYO3B</i>	148	<i>MAPK12</i>	182	<i>PTK9</i>	216	<i>STK29</i>
13	<i>HSMDPKIN</i>	47	<i>MAP2K5</i>	81	<i>MPP3</i>	115	<i>CDKN2B</i>	149	<i>PANK1</i>	183	<i>PFKFB2</i>	217	<i>TLK2</i>
14	<i>CDKN3</i>	48	<i>MARK1</i>	82	<i>HK1</i>	116	<i>PRKAA1</i>	150	<i>MYO3A</i>	184	<i>PRKAR2A</i>	218	<i>NBEA</i>
15	<i>EPHB2</i>	49	<i>MPZL1</i>	83	<i>PRKCM</i>	117	<i>CHUK</i>	151	<i>PTPRG</i>	185	<i>MAPKAPK2</i>	219	<i>FZD5</i>
16	<i>PRPSAP2</i>	50	<i>KIF13B</i>	84	<i>NME6</i>	118	<i>PAK6</i>	152	<i>APPL</i>	186	<i>TAO1</i>	220	<i>IRS1</i>
17	<i>MGC8407</i>	51	<i>PRKCABP</i>	85	<i>STK32B</i>	119	<i>CHRM1</i>	153	<i>FZD7</i>	187	<i>EDG6</i>	221	<i>STK6</i>
18	<i>GSK3B</i>	52	<i>MAP4K3</i>	86	<i>CALCA</i>	120	<i>PAK4</i>	154	<i>EPHA3</i>	188	<i>CCR6</i>	222	<i>GNAT2</i>
19	<i>NAGK</i>	53	<i>PDGFRA</i>	87	<i>MAPK13</i>	121	<i>KDR</i>	155	<i>HIPK4</i>	189	<i>PIK4CB</i>	223	<i>EDNRA</i>
20	<i>FLJ13052</i>	54	<i>NEK6</i>	88	<i>GNB1</i>	122	<i>IKBKB</i>	156	<i>PIK3R3</i>	190	<i>TXNDC3</i>	224	<i>ADRA2A</i>
21	<i>NPR1</i>	55	<i>PRKCA</i>	89	<i>PRKAR2B</i>	123	<i>CDKN2C</i>	157	<i>CX3CR1</i>	191	<i>ASP</i>	225	<i>BMPR1A</i>
22	<i>ITGB1BP1</i>	56	<i>PTK9L</i>	90	<i>PIK3R2</i>	124	<i>CDKN2D</i>	158	<i>MAPK4</i>	192	<i>RIPK2</i>	226	<i>BLK</i>

23	MGC16169	57	MAP3K3	91	F2R	125	F2RL2	159	MAP3K1 ₄	193	CSNK1G3	227	NEK3
24	PFKFB3	58	MRC2	92	GNA14	126	PKMYT1	160	BAI2	194	EBI2	228	NEK2
25	PIP5K2A	59	EPHA8	93	PIK3CG	127	CNR1	161	CKMT1	195	EDG4	229	ASK
26	NEK8	60	PYCS	94	BDKRB ₁	128	GNG11	162	OSR1	196	INSRR	230	CRHR2
27	FLJ34389	61	EPHA4	95	AKT3	129	TEX14	163	C9ORF9 ₈	197	DRD1	231	MAP3K13
28	CAMK2A	62	CDKL1	96	GSK3A	130	FRK	164	PKM2	198	MAPK3	232	FGR
29	PTPN5	63	PACE-1	97	MAP2K ₃	131	SCYL1	165	PTPRR	199	SCAP1	233	AGTRL1
30	CDK4	64	TNIK	98	PRPSAP ₁	132	DAPK2	166	TP53RK	200	MAP3K8		
31	PIM2	65	EPHB4	99	IHPK3	133	PRKCI	167	DRD5	201	PDXK		
32	PANK3	66	PRKAA2	100	PRPS2	134	EPHA7	168	PTPRJ	202	MAP3K11		
33	BMPRI1B	67	RAF1	101	DGKG	135	NEK7	169	CDKL5	203	SQSTM1		
34	DLG1	68	F2RL1	102	CLK2	136	PIK3CA	170	CCRL1	204	IHPK2		

Table S2. The top 100 target kinases identified in HCC70 TNBC cell line using 3D RNAi kinome-wide library screening.

HCC70															
Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol	Rank	Gene Symbol
1	DGKB	36	FGR	71	HCK	106	CSNK1A1L	141	MAPK6	176	DUSP8	211	GSK3A	246	GPR155
2	CELSR2	37	BCKDK	72	SCYL1	107	CAMK1D	142	DLG4	177	MARK ₂	212	AATK	247	RET
3	MASTL	38	STK23	73	TTK	108	FN3KRP	143	DKFZP761P0423	178	FRDA	213	PDXK	248	CDKN2C
4	GIPR	39	CLK3	74	EPHA5	109	CDKN1B	144	GNAO1	179	KHK	214	ERBB3	249	TTN
5	URKL1	40	CASK	75	PFTK1	110	MGC16169	145	ADRBK2	180	CCRL2	215	TPK1	250	TOPK
6	DGKZ	41	DGKA	76	GUK1	111	FLJ10458	146	CDADC1	181	LMTK2	216	LIMK1	251	PIM2

7	DUSP10	42	PLK2	77	MGC560 1	112	PACE-1	147	FLJ10060	182	AURK C	217	GLP2R	252	IRS1
8	BRAF	43	CAMK1	78	EPHA1	113	FER	148	FZD9	183	FPR1	218	DYRK3	253	RNASEL
9	DGKE	44	PGK1	79	APEG1	114	CSNK2A1	149	TTBK1	184	CDK8	219	PCTK3	254	FLJ25006
10	BAI2	45	ADRB2	80	ARK5	115	CSNK1G3	150	KIT	185	C3AR1	220	GNB4	255	IKBKE
11	EPHB1	46	ITK	81	DUSP22	116	TNNI3K	151	BMX	186	PAPSS 1	221	RP2	256	EGFR
12	DUSP4	47	DDR1	82	FKSG83	117	GRK6	152	PCTK2	187	CDKN2 D	222	IGF1R	257	PIM1
13	FLJ32685	48	LIM	83	GFRA2	118	CCR2	153	ULK1	188	ROCK2	223	C5	258	TGFBR2
14	MAP2K1 IP1	49	CDKN1C	84	PRPS1	119	TGFBR1	154	CALCRL	189	BLR1	224	TESK2	259	MAPK3
15	CDK5R2	50	RFP	85	CAMK2 D	120	CHUK	155	DEFB4	190	EDG5	225	ARRB1	260	CDC2
16	BMPR2	51	ICK	86	HIPK2	121	IKBKB	156	ADRB2	191	EPHB3	226	ELOVL4	261	CDKN3
17	AVPR1B	52	MAP3K2	87	FZD6	122	GNAT1	157	EBI2	192	CINP	227	EDG8	262	PFKFB4
18	FLJ10842	53	MGC8407	88	DYRK1B	123	PRKCABP	158	APPL	193	ERBB4	228	ACVRL1	263	CDK5
19	RPS6KA 5	54	CD7	89	FGFR2	124	CYSLTR1	159	PRKCQ	194	C7ORF 16	229	CXCL12	264	ACVR1C
20	STK38L	55	KIF13B	90	CDC7	125	KSR2	160	AAK1	195	RAGE	230	CCR1	265	DLG1
21	ANKRD3	56	AVPR1A	91	CASR	126	GTF2H1	161	CDC42BP B	196	DGUO K	231	CARD10	266	PRKCH
22	ADRA1B	57	AK3L1	92	MAP4K4	127	MST4	162	GUCY2F	197	LOC91 807	232	PI4KII	267	F2RL1
23	VRK2	58	MPZL1	93	ARAF1	128	AKT3	163	PDK3	198	SGKL	233	GNAS	268	NYD-SP25
24	GNG11	59	MGC4796	94	RIPK1	129	AGTR2	164	CHRM3	199	DYRK4	234	CAMK2A	269	RPS6KB1
25	CCL17	60	C5R1	95	CALCR	130	TAF1	165	FUK	200	BAI1	235	KIAA1399	270	RPS6KC1
26	BMPR1B	61	FZD5	96	C17ORF 35	131	STK24	166	CSNK1G 1	201	CAMK 2G	236	KDR	271	FLJ35107
27	BMP2K	62	GIT2	97	SMAD7	132	DGKD	167	CCL2	202	RYK	237	DUSP1	272	PRPSAP1
28	CRY1	63	CARD14	98	ADORA 3	133	EDG4	168	SNARK	203	TK2	238	CCR8	273	BRS3

29	<i>LOC115704</i>	64	<i>SOCS1</i>	99	<i>HRI</i>	134	<i>ADCYAP1R1</i>	169	<i>PRPS2</i>	204	<i>PFKFB1</i>	239	<i>DLG3</i>	274	<i>PAK6</i>
30	<i>ICF45</i>	65	<i>EEF2K</i>	100	<i>PRKDC</i>	135	<i>PDK4</i>	170	<i>FASTK</i>	205	<i>FPRL2</i>	240	<i>GMFB</i>	275	<i>IRAK2</i>
31	<i>CSF1R</i>	66	<i>EDG3</i>	101	<i>FRAP1</i>	136	<i>CXCL10</i>	171	<i>CXCL9</i>	206	<i>TRIO</i>	241	<i>CNKSR1</i>	276	<i>SAST</i>
32	<i>DGKG</i>	67	<i>MPP2</i>	102	<i>LTK</i>	137	<i>SGK</i>	172	<i>BUB1B</i>	207	<i>PIK3CA</i>	242	<i>ADORA2B</i>	277	<i>STYK1</i>
33	<i>GCK</i>	68	<i>CXCL3</i>	103	<i>KIS</i>	138	<i>MAP4K3</i>	173	<i>ADK</i>	208	<i>GNAQ</i>	243	<i>ILKAP</i>	278	<i>PRKWNK2</i>
34	<i>AKAP1</i>	69	<i>BCR</i>	104	<i>EPHA8</i>	139	<i>RIPK2</i>	174	<i>CAMK4</i>	209	<i>SHC1</i>	244	<i>CRHR2</i>	279	<i>EDG1</i>
35	<i>TLR3</i>	70	<i>CDKL1</i>	105	<i>PRKACB</i>	140	<i>CCL3</i>	175	<i>ADORA1</i>	210	<i>PFKL</i>	245	<i>C7ORF9</i>		

Table S3. The 65 common target genes from CAL51 and HCC70 using 3D RNAi kinome-wide library screening.

65 Common Target Genes									
<i>ACVRL1</i>	<i>AKT3</i>	<i>APPL</i>	<i>AVPR1B</i>	<i>BAI2</i>	<i>BMPR1B</i>	<i>C5R1</i>	<i>CAMK2A</i>	<i>CCL3</i>	<i>CDKL1</i>
<i>CDKN2C</i>	<i>CDKN2D</i>	<i>CDKN3</i>	<i>CHUK</i>	<i>CRHR2</i>	<i>CSNK1G3</i>	<i>DGKG</i>	<i>DLG1</i>	<i>EBI2</i>	<i>EDG4</i>
<i>EDG5</i>	<i>EEF2K</i>	<i>EPHA5</i>	<i>EPHA8</i>	<i>EPHB1</i>	<i>EPHB3</i>	<i>F2RL1</i>	<i>FGR</i>	<i>FUK</i>	<i>FZD5</i>
<i>GNB4</i>	<i>GNG11</i>	<i>GSK3A</i>	<i>GUK1</i>	<i>HIPK2</i>	<i>IKBKB</i>	<i>IKBKE</i>	<i>IRS1</i>	<i>KDR</i>	<i>KIF13B</i>
<i>LIM</i>	<i>MAP3K2</i>	<i>MAP4K3</i>	<i>MAP4K4</i>	<i>MAPK3</i>	<i>MAPK6</i>	<i>MGC16169</i>	<i>MGC5601</i>	<i>MGC8407</i>	<i>MPZL1</i>
<i>PACE-1</i>	<i>PAK6</i>	<i>PCTK3</i>	<i>PDXK</i>	<i>PIK3CA</i>	<i>PIM1</i>	<i>PIM2</i>	<i>PRKCABP</i>	<i>PRPS2</i>	<i>PRPSAP1</i>
<i>RAGE</i>	<i>RIPK2</i>	<i>SCYL1</i>	<i>SNARK</i>	<i>TPK1</i>					

Table S4. The 24 AS-related proteins used in RPPA analysis.

Apoptosis Related 24 Proteins from RPPA Analysis			
H2AX pS140	FoxO3 pS318	Annexin I	PARP
Bcl2	Bcl-XL	Bax	Wee1
Caspase 8	JNK pT183/Y185	Bim	Beclin
Bak	Caspase 3	Cleaved-Caspase 7	JNK2
c-Jun pS73	Wee1 pS642	Annexin VII	XBP1
FoxO3a	IAP2	Bid	Mcl1

Table S5. Combinational effect of ONC201 with seven targeted kinase inhibitors. CI values <0.10 indicated very strong synergism; 0.10–0.30, strong synergism; 0.31–0.70, synergism; 0.71–0.85, moderate synergism; 0.86–0.90, slight synergism; 0.91–1.10, nearly additive; 1.11–1.20, slight antagonism; 1.21–1.45, moderate antagonism; 1.46–3.30, antagonism; 3.31–10, strong antagonism; >10, very strong antagonism. Fa, fractional cell killing effect of drug treatment.

ONC201/Trametinib

Combination (μM)		MDA-MB-231	
ONC201	Trametinib	Fa	CI
0.27	0.32	0.41	1.25
0.54	0.63	0.79	0.37
1.07	1.25	0.86	0.43
2.13	2.50	0.98	0.14
4.25	5.00	1.00	0.11

Combination (μM)		MDA-MB-453	
ONC201	Trametinib	Fa	CI
0.27	0.32	0.50	0.20
0.54	0.63	0.53	0.36
1.07	1.25	0.81	0.34
2.13	2.50	0.93	0.35
4.25	5.00	0.96	0.53

Combination (μM)		SUM149	
ONC201	Trametinib	Fa	CI
1.07	1.25	0.75	0.22
2.13	2.50	0.97	0.09
4.25	5.00	0.99	0.11
8.50	10.00	0.98	0.27
16.90	20.00	0.98	0.49

Combination (μM)		HCC70	
ONC201	Trametinib	Fa	CI
1.07	1.25	0.42	0.11
2.13	2.50	0.58	0.07
4.25	5.00	0.70	0.07
8.50	10.00	0.74	0.12
16.90	20.00	0.88	0.08

ONC201/Ulixertinib

Combination (μM)		MDA-MB-231	
ONC201	Ulixertinib	Fa	CI
0.27	0.32	0.56	0.91
0.54	0.63	0.69	0.95
1.07	1.25	0.78	1.16
2.13	2.50	0.94	0.49
4.25	5.00	0.97	0.57

Combination (μM)		MDA-MB-453	
ONC201	Ulixertinib	Fa	CI
0.54	0.63	0.46	0.76
1.07	1.25	0.81	0.49
2.13	2.50	0.94	0.40
4.25	5.00	0.95	0.75
8.50	10.00	0.98	0.87

Combination (μM)		SUM149	
ONC201	Ulixertinib	Fa	CI
1.07	1.25	0.74	0.33
2.13	2.50	0.80	0.49
4.25	5.00	0.80	0.97
8.50	10.00	0.90	1.03
16.90	20.00	0.90	2.05

Combination (μM)		HCC70	
ONC201	Ulixertinib	Fa	CI
1.07	1.25	0.18	1.29
2.13	2.50	0.37	0.93
4.25	5.00	0.57	0.78
8.50	10.00	0.96	0.08
16.90	20.00	0.99	0.03

ONC201/VX-11e

Combination (μM)		MDA-MB-453	
ONC201	VX-11e	Fa	CI
0.54	0.63	0.55	0.42
1.07	1.25	0.84	0.34
2.13	2.50	0.97	0.24
4.25	5.00	0.99	0.22
8.50	10.00	1.00	0.18

Combination (μM)		MDA-MB-231	
ONC201	VX-11e	Fa	CI
0.27	0.32	0.47	0.78
0.54	0.63	0.64	0.86
1.07	1.25	0.79	0.91
2.13	2.50	0.96	0.45
4.25	5.00	0.99	0.33

Combination (μM)		SUM149	
ONC201	VX-11e	Fa	CI
1.07	1.25	0.86	0.16
2.13	2.50	0.90	0.24
4.25	5.00	0.90	0.48
8.50	10.00	0.90	0.97
16.90	20.00	0.90	1.93

Combination (μM)		HCC70	
ONC201	VX-11e	Fa	CI
1.07	1.25	0.16	0.89
2.13	2.50	0.42	0.58
4.25	5.00	0.67	0.52
8.50	10.00	0.95	0.17
16.90	20.00	0.99	0.11

ONC201/MK-2206

Combination (μM)		MDA-MB-453	
ONC201	MK-2206	Fa	CI
0.27	0.32	0.64	0.70
0.54	0.63	0.87	0.37
1.07	1.25	0.95	0.30
2.13	2.50	0.98	0.27
4.25	5.00	1.00	0.21

ONC201/PF04691502

Combination (μM)		MDA-MB-453	
ONC201	PF04391052	Fa	CI
0.27	0.32	0.89	0.44
0.54	0.63	0.89	0.81
1.07	1.25	0.89	1.66
2.13	2.50	0.90	3.07
4.25	5.00	0.90	6.05

ONC201/Buparlisib

Combination		MDA-MB-453	
ONC201	Buparlisib	Fa	CI
0.07	0.08	0.30	0.41
0.14	0.16	0.40	0.59
0.27	0.32	0.50	0.87
0.54	0.63	0.58	1.37
1.07	1.25	0.90	0.68

ONC201/Dactolisib

Combination		MDA-MB-453	
ONC201	Dactolisib	Fa	CI
0.14	0.16	0.64	48.17
0.27	0.32	0.75	15.26
0.54	0.63	0.77	18.02
1.07	1.25	0.77	38.72
2.13	2.50	0.77	72.98

Combination (μM)		MDA-MB-231	
ONC201	MK-2206	Fa	CI
1.07	1.25	0.21	1.23
2.13	2.50	0.91	0.28
4.25	5.00	0.96	0.35
8.50	10.00	0.98	0.47
16.90	20.00	0.99	0.62

Combination (μM)		MDA-MB-231	
ONC201	PF04391052	Fa	CI
0.14	0.16	0.26	2.19
0.27	0.32	0.49	2.08
0.54	0.63	0.69	2.16
1.07	1.25	0.79	2.92
2.13	2.50	0.81	5.33

Combination		MDA-MB-231	
ONC201	Buparlisib	Fa	CI
0.54	0.63	0.36	2.63
1.07	1.25	0.64	2.27
2.13	2.50	0.83	2.15
4.25	5.00	0.84	3.98
8.50	10.00	0.85	7.71

Combination		MDA-MB-231	
ONC201	Dactolisib	Fa	CI
0.27	0.32	0.42	3299.18
0.54	0.63	0.53	1063.83
1.07	1.25	0.63	504.16
2.13	2.50	0.79	43.43
4.25	5.00	0.86	15.03

Combination (μM)		SUM149	
ONC201	MK-2206	Fa	CI
1.07	1.25	0.61	0.38
2.13	2.50	0.77	0.45
4.25	5.00	0.79	0.81
8.50	10.00	0.99	0.12
16.90	20.00	1.00	0.07

Combination (μM)		SUM149	
ONC201	PF04391052	Fa	CI
0.27	0.32	0.30	0.49
0.54	0.63	0.31	0.95
1.07	1.25	0.95	0.28
2.13	2.50	0.98	0.33
4.25	5.00	0.98	0.74

Combination		SUM149	
ONC201	Buparlisib	Fa	CI
1.07	1.25	0.91	0.28
2.13	2.50	0.96	0.32
4.25	5.00	0.98	0.50
8.50	10.00	0.99	0.78
16.90	20.00	1.00	0.67

Combination		SUM149	
ONC201	Dactolisib	Fa	CI
0.14	0.16	0.30	2.20
0.27	0.32	0.40	1.97
0.54	0.63	0.50	1.89
1.07	1.25	0.54	2.89
2.13	2.50	0.75	1.29

Combination (μM)		HCC70	
ONC201	MK-2206	Fa	CI
0.54	0.63	0.52	0.81
1.07	1.25	0.59	0.82
2.13	2.50	0.73	0.36
4.25	5.00	0.87	0.10
8.50	10.00	0.90	0.11

Combination (μM)		HCC70	
ONC201	PF04391052	Fa	CI
0.07	0.08	0.37	1.77
0.14	0.16	0.57	1.50
0.27	0.32	0.75	1.24
0.54	0.63	0.87	1.00
1.07	1.25	0.90	1.41

Combination		HCC70	
ONC201	Buparlisib	Fa	CI
0.27	0.32	0.30	0.90
0.54	0.63	0.31	1.74
1.07	1.25	0.87	0.49
2.13	2.50	0.87	1.00
4.25	5.00	0.92	1.32

Combination		HCC70	
ONC201	Dactolisib	Fa	CI
1.07	1.25	0.10	133.16
2.13	2.50	0.19	101.41
4.25	5.00	0.57	20.76
8.50	10.00	0.74	15.65
16.90	20.00	0.76	27.63




Figure S1. Dose-response of ONC201 in TNBC cell lines with Vanderbilt TNBC molecular subtypes. TNBC cells were treated with ONC-201 for 5 days, and viability was measured by using sulforhodamine-B assays. Data shown are representative of three experiments with similar results.




Figure S2. Western blotting. CAL51 and HCC70 cells were transfected with siClpP (SASI_Hs01_00025718, Sigma-Aldrich, USA), pCMV6-ClpP-Myc-DDK or control vectors (OriGene, USA) by Neon electroporation transfection kit (Invitrogen, USA). **(A)** Overexpression or knockdown of ClpP by expression vector or siRNA. **(B)** ONC-201 reduced ClpP expression in ClpP-overexpressed TNBC cell lines. **(C)** Trametinib does not affect on ClpP expression.